JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
JMP證券啓動對summit therapeutics的覆蓋，預測市場表現優異，宣佈目標價32美元
JMP Securities analyst Reni Benjamin initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform rating and announces Price Target of $32.
JMP證券分析師Reni Benjamin啓動對納斯達克summit therapeutics (NASDAQ:SMMT)的覆蓋，給予市場表現優異評級，並宣佈目標價32美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。